Successful Treatment of Brunsting-Perry Cicatricial Pemphigoid With Dupilumab

We present the case of a 63-year-old patient with history of Brunsting-Perry cicatricial pemphigoid who proved refractory to multiple conventional therapies but was successfully treated with a dupilumab regimen of 300 mg every two weeks. This case suggests the potential role of dupilumab in the management of Brunsting-Perry cicatricial pemphigoid. J Drugs Dermatol. 2021;20(10):1113-1115. doi:10.36849/JDD.6032.PMID:34636516 | DOI:10.36849/JDD.6032
Source: Journal of Drugs in Dermatology - Category: Dermatology Authors: Source Type: research

Related Links:

Dermatitis. 2021 Sep 27. doi: 10.1097/DER.0000000000000792. Online ahead of print.ABSTRACTBACKGROUND: Although bullous pemphigoid (BP), atopic dermatitis (AD), and allergic rhinitis (AR) are associated with shared pathogenic mechanisms the epidemiological relationship between these conditions remains to be investigated.OBJECTIVE: To evaluate the bidirectional association of BP with AD and AR.METHODS: A population-based retrospective cohort study was performed comparing BP patients (n = 3924) with age-, sex-, and ethnicity-matched control subjects (n = 19,280), with respect to incident cases of AD and AR. A case-control des...
Source: Dermatitis - Category: Dermatology Authors: Source Type: research
Australas J Dermatol. 2021 Aug 26. doi: 10.1111/ajd.13692. Online ahead of print.NO ABSTRACTPMID:34448201 | DOI:10.1111/ajd.13692
Source: The Australasian Journal of Dermatology - Category: Dermatology Authors: Source Type: research
This is a rare case of a 73-year-old female who developed generalized classic bullous pemphigoid (BP), likely from smoldering pre-bullous or eczematous BP, during radiation therapy (RT) for breast cancer. Prior to RT for invasive ductal carcinoma of the right breast, the patient was referred to dermatology for a chronic pruritic rash. Given the pruritic erythematous papules with overlying erosions, excoriations, and white atrophic scars on her chest, back, arms and legs that had been present for several years without specific triggers, she was diagnosed with prurigo simplex with non-specific eczematous dermatitis and presc...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Source Type: research
Dermatitis. 2021 Aug 16. doi: 10.1097/DER.0000000000000776. Online ahead of print.ABSTRACTAs treatment with immune checkpoint inhibitors (CPIs) for cancer increases, so has the incidence of immune-related cutaneous adverse events (irCAEs). These toxicities can significantly impact quality of life and may be dose-limiting. Current guidelines for irCAEs offer only corticosteroids or CPI discontinuation. Evidence supports biologic immunomodulatory therapies when corticosteroids fail or need avoidance. A review of literature from 2010 to 2020 yielded 45 articles, resulting in 185 irCAEs, including bullous pemphigoid-like erupt...
Source: Dermatitis - Category: Dermatology Authors: Source Type: research
J Mol Med (Berl). 2021 Aug 9. doi: 10.1007/s00109-021-02105-y. Online ahead of print.ABSTRACTAdenosine triphosphate-binding cassette subfamily B member 1 (ABCB1), also known as permeability glycoprotein, multidrug-resistant protein 1, or cluster of differentiation 243 (CD243), is a crucial protein for purging foreign substances from cells. The functions of ABCB1 have been investigated extensively for their roles in cancer, stem cells, and drug resistance. Abundant pharmacogenetic studies have been conducted on ABCB1 and its association with treatment responsiveness to various agents, particularly chemotherapeutic and immun...
Source: Molecular Medicine - Category: Molecular Biology Authors: Source Type: research
ConclusionsThe clinico-epidemiological characteristics vary among the types of autoimmune bullous diseases. Females were more predominant in most of them. Sudanese patients tended in general to present at a younger age than other populations. The pool of Sudanese patients with autoimmune bullous diseases is large which requires investigation for the local risk factors and presents a field for future trials.
Source: PLoS One - Category: Biomedical Science Authors: Source Type: research
AbstractUstekinumab is approved for the treatment of psoriasis and Crohn ’s disease. Because many dermatological conditions are due to immune-mediated development, ustekinumab may be effective in other conditions. A systematic review of the off-label uses of ustekinumab, as well as on-label adverse effect, was performed, reporting on clinical improvement. MEDLINE, Emba se, Web of Science, and Cochrane databases were searched for studies regarding ustekinumab treatment of rativa (HS), lichen planus (LP), pyoderma gangrenosum (PG), pityriasis rubra pilaris (PRP), cutalopecia areata (AA), atopic dermatitis (AD), Bechet&...
Source: Archives of Dermatological Research - Category: Dermatology Source Type: research
We present an 80-year-old man with moderate to severe bullous pemphigoid successfully treated with dupilumab.PMID:33999579
Source: Dermatol Online J - Category: Dermatology Authors: Source Type: research
More News: Allergy & Immunology | Dermatitis | Dermatology | Pemphigoid | Skin